Cellular Hope Institute Expands International Patient Programs for U.S. and Canadian Markets
FOR IMMEDIATE RELEASE
- New premium, highly personalized international patient program targets individuals traveling from the United States and Canada
- Programs combine physician assessment, regenerative medicine, longevity technologies, diagnostics, and wellness services
- Expansion reflects growing North American interest in destination-based longevity medicine
MIAMI, FL — Cellular Hope Institute, the clinical division of Global Stem Cells Group and Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG), today announced an expanded international patient strategy targeting individuals traveling from the United States and Canada to its Cancun facilities.
The institute is developing comprehensive, premium medical-wellness programs combining physician assessment, regenerative medicine, longevity technologies, diagnostics, and hospitality-oriented patient coordination where appropriate. The programs are intended for international patients seeking a highly personalized, destination-based longevity and regenerative medicine experience.
Cellular Hope Institute described the offering as a premium, highly personalized international patient program, reflecting the individualized nature of physician-directed longevity care rather than a standardized package.
“More patients in the U.S. and Canada are looking for a genuinely comprehensive longevity experience, not just a single procedure,” said David Christensen, Chief Executive Officer and President of Regenerative Medical Technology Group, Inc. “This program is built around that — physician assessment first, then a program built around the individual patient.”
About Regenerative Medical Technology Group, Inc.
Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG) is an SEC-reporting regenerative medicine company operating through its wholly owned subsidiary Global Stem Cells Group and Global Stem Cells Group’s operating divisions — Cellgenic, the International Society for Stem Cell Application (ISSCA), and Cellular Hope Institute. The Company’s network reaches physicians and patients across more than 30 countries, combining biologics and regenerative-medicine product commercialization, physician education and certification, and physician-directed clinical services. RMTG’s stated mission is to help physicians make the benefits of regenerative medicine available to patients worldwide.
About Cellular Hope Institute
Cellular Hope Institute, the clinical division of Global Stem Cells Group and Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG), is based in Cancun, Mexico, and provides physician-directed regenerative medicine, longevity, and wellness programs to international patients.
Forward-Looking Statements
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, and other factors — including regulatory developments, market acceptance, operational execution, competitive conditions, currency and economic factors, and the Company’s ability to maintain compliance with applicable laws — that could cause actual results to differ materially from those expressed or implied. Words such as “plan,” “forecast,” “anticipate,” “estimate,” “project,” “intend,” “expect,” “should,” “believe,” and similar expressions are intended to identify forward-looking statements. These statements are based on management’s current expectations and are qualified in their entirety by the risks described more fully in the Company’s filings with the U.S. Securities and Exchange Commission. Any forward-looking statement regarding future revenues, market penetration, or operational expansion reflects management’s current belief only and should not be read as a guarantee of any outcome. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.
Contact
- Published in Press Releases
Cellular Hope Institute Expands Cancun Clinical Facilities and Longevity Platform
FOR IMMEDIATE RELEASE
- Expansion introduces additional physician-directed longevity, wellness, and complementary technology capabilities
- Investment builds on Cellgenic’s parallel laboratory expansion in the same city
- Cellular Hope Institute positions Cancun as a comprehensive destination for international regenerative medicine and longevity patients
MIAMI, FL — Cellular Hope Institute, the clinical division of Global Stem Cells Group and Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG), today announced a significant expansion of its clinical facilities in Cancun, Mexico, introducing additional physician-directed longevity, wellness, and complementary technology capabilities.
The expansion adds hyperbaric medicine, red-light/photobiomodulation therapies, PEMF, radiofrequency technologies, molecular hydrogen therapies, EBOO/EVO, and therapeutic plasma exchange (TPE) to the institute’s clinical capabilities.
The expansion is designed to create a more comprehensive destination for international patients seeking physician-directed regenerative medicine and longevity programs, and complements Cellgenic’s parallel laboratory expansion in the same city. Cellular Hope Institute was clear that all programs remain physician-directed and made no claims regarding specific health outcomes.
“Patients traveling internationally for longevity and regenerative medicine care want more than a single treatment — they want a comprehensive, physician-directed program,” said David Christensen, Chief Executive Officer and President of Regenerative Medical Technology Group, Inc. “This expansion is about building that in Cancun.”
About Regenerative Medical Technology Group, Inc.
Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG) is an SEC-reporting regenerative medicine company operating through its wholly owned subsidiary Global Stem Cells Group and Global Stem Cells Group’s operating divisions — Cellgenic, the International Society for Stem Cell Application (ISSCA), and Cellular Hope Institute. The Company’s network reaches physicians and patients across more than 30 countries, combining biologics and regenerative-medicine product commercialization, physician education and certification, and physician-directed clinical services. RMTG’s stated mission is to help physicians make the benefits of regenerative medicine available to patients worldwide.
About Cellular Hope Institute
Cellular Hope Institute, the clinical division of Global Stem Cells Group and Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG), is based in Cancun, Mexico, and provides physician-directed regenerative medicine, longevity, and wellness programs to international patients.
Forward-Looking Statements
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, and other factors — including regulatory developments, market acceptance, operational execution, competitive conditions, currency and economic factors, and the Company’s ability to maintain compliance with applicable laws — that could cause actual results to differ materially from those expressed or implied. Words such as “plan,” “forecast,” “anticipate,” “estimate,” “project,” “intend,” “expect,” “should,” “believe,” and similar expressions are intended to identify forward-looking statements. These statements are based on management’s current expectations and are qualified in their entirety by the risks described more fully in the Company’s filings with the U.S. Securities and Exchange Commission. Any forward-looking statement regarding future revenues, market penetration, or operational expansion reflects management’s current belief only and should not be read as a guarantee of any outcome. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.
Contact
- Published in Press Releases
ISSCA Concludes 2026 International Conference Calendar in Dubai, December 4–5
FOR IMMEDIATE RELEASE
- Conference marks ISSCA’s return to Dubai, United Arab Emirates, December 4–5 at the Hyatt Regency Dubai Creek Heights
- Event closes ISSCA’s international conference calendar for the year
- Release quantifies the year’s countries reached and conferences held, with final physician-trained and certification totals confirmed at publication
MIAMI, FL — The International Society for Stem Cell Application (ISSCA), the physician-education division of Global Stem Cells Group and Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG), today announced ISSCA 129, its return to Dubai, United Arab Emirates, December 4–5 at the Hyatt Regency Dubai Creek Heights, closing ISSCA’s international conference calendar for the year.
The Dubai conference caps a year that included ISSCA events across more than a dozen countries — including Paraguay, Pakistan, Portugal, Brazil, the Dominican Republic, Peru, Argentina, Turkey, Mexico, Bolivia, and Colombia — alongside continued growth of its Online Academy and certification programs. Final totals for physicians trained and certifications issued across the year will be confirmed at time of publication.
ISSCA positioned Dubai as a fitting close to the calendar given the UAE’s role as a regional hub connecting Middle Eastern, South Asian, and African physician communities to ISSCA’s education network.
“Closing the year in Dubai lets us look back at a genuinely global conference calendar — Latin America, the Middle East, and everywhere in between,” said David Christensen, Chief Executive Officer and President of Regenerative Medical Technology Group, Inc. “It’s also where we start planning next year’s expansion.”
About Regenerative Medical Technology Group, Inc.
Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG) is an SEC-reporting regenerative medicine company operating through its wholly owned subsidiary Global Stem Cells Group and Global Stem Cells Group’s operating divisions — Cellgenic, the International Society for Stem Cell Application (ISSCA), and Cellular Hope Institute. The Company’s network reaches physicians and patients across more than 30 countries, combining biologics and regenerative-medicine product commercialization, physician education and certification, and physician-directed clinical services. RMTG’s stated mission is to help physicians make the benefits of regenerative medicine available to patients worldwide.
About ISSCA
The International Society for Stem Cell Application (ISSCA), the physician-education division of Global Stem Cells Group and Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG), was founded in 2009 and has trained more than 12,000 physicians across more than 45 countries in regenerative medicine, longevity medicine, and related disciplines through certifications, fellowships, conferences, and online education.
Forward-Looking Statements
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, and other factors — including regulatory developments, market acceptance, operational execution, competitive conditions, currency and economic factors, and the Company’s ability to maintain compliance with applicable laws — that could cause actual results to differ materially from those expressed or implied. Words such as “plan,” “forecast,” “anticipate,” “estimate,” “project,” “intend,” “expect,” “should,” “believe,” and similar expressions are intended to identify forward-looking statements. These statements are based on management’s current expectations and are qualified in their entirety by the risks described more fully in the Company’s filings with the U.S. Securities and Exchange Commission. Any forward-looking statement regarding future revenues, market penetration, or operational expansion reflects management’s current belief only and should not be read as a guarantee of any outcome. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.
Contact
- Published in Press Releases
ISSCA Returns to São Paulo for Second Brazil Congress, November 20–21
FOR IMMEDIATE RELEASE
- Second São Paulo congress of 2026 runs November 20–21, following ISSCA’s April program in the city
- Additional congress reflects Brazil’s position as one of ISSCA’s highest-priority Latin American markets
- Event runs alongside Cellgenic’s permanent operations launch in Brazil
MIAMI, FL — The International Society for Stem Cell Application (ISSCA), the physician-education division of Global Stem Cells Group and Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG), today announced ISSCA 127, its second São Paulo, Brazil congress of 2026, taking place November 20–21 in the city’s Vila Olímpia district, following ISSCA’s first 2026 Brazil program in April.
Running two Brazil events in a single year is a frequency ISSCA has not previously applied to the market, reflecting Brazil’s scale and the organization’s broader Latin American expansion alongside Cellgenic’s commercial buildout.
The second São Paulo congress runs alongside Cellgenic’s establishment of permanent operations in Brazil, reinforcing ISSCA and Cellgenic’s coordinated market presence in one of Latin America’s largest healthcare markets.
“Brazil earned a second date on our calendar this year,” said David Christensen, Chief Executive Officer and President of Regenerative Medical Technology Group, Inc. “Between ISSCA’s education programming and Cellgenic’s commercial buildout, Brazil is becoming one of our most active single markets anywhere in the world.”
About Regenerative Medical Technology Group, Inc.
Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG) is an SEC-reporting regenerative medicine company operating through its wholly owned subsidiary Global Stem Cells Group and Global Stem Cells Group’s operating divisions — Cellgenic, the International Society for Stem Cell Application (ISSCA), and Cellular Hope Institute. The Company’s network reaches physicians and patients across more than 30 countries, combining biologics and regenerative-medicine product commercialization, physician education and certification, and physician-directed clinical services. RMTG’s stated mission is to help physicians make the benefits of regenerative medicine available to patients worldwide.
About ISSCA
The International Society for Stem Cell Application (ISSCA), the physician-education division of Global Stem Cells Group and Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG), was founded in 2009 and has trained more than 12,000 physicians across more than 45 countries in regenerative medicine, longevity medicine, and related disciplines through certifications, fellowships, conferences, and online education.
Forward-Looking Statements
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, and other factors — including regulatory developments, market acceptance, operational execution, competitive conditions, currency and economic factors, and the Company’s ability to maintain compliance with applicable laws — that could cause actual results to differ materially from those expressed or implied. Words such as “plan,” “forecast,” “anticipate,” “estimate,” “project,” “intend,” “expect,” “should,” “believe,” and similar expressions are intended to identify forward-looking statements. These statements are based on management’s current expectations and are qualified in their entirety by the risks described more fully in the Company’s filings with the U.S. Securities and Exchange Commission. Any forward-looking statement regarding future revenues, market penetration, or operational expansion reflects management’s current belief only and should not be read as a guarantee of any outcome. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.
Contact
- Published in Press Releases
ISSCA Announces Bogotá, Colombia Conference, November 27–28
FOR IMMEDIATE RELEASE
- Conference runs November 27–28 at the Hilton Bogotá Corferias, continuing ISSCA’s expansion of physician education throughout Latin America
- Program targets more than 250 physician attendees across flagship and peptide-medicine certification tracks
- Event complements Cellgenic’s parallel commercial expansion into Colombia
MIAMI, FL — The International Society for Stem Cell Application (ISSCA), the physician-education division of Global Stem Cells Group and Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG), today announced ISSCA 128, its conference in Bogotá, Colombia, taking place November 27–28 at the Hilton Bogotá Corferias.
The Bogotá conference continues ISSCA’s ongoing expansion of physician education throughout Latin America, with a program built around the organization’s flagship and peptide-medicine certification tracks. Confirmed faculty and full workshop programming will be published as the event date approaches.
The event runs alongside Cellgenic’s operational expansion into Colombia, reinforcing ISSCA and Cellgenic’s coordinated approach to entering new Latin American markets through both education and commercial channels.
“Bogotá gives ISSCA a direct connection to Colombia’s physician community right as Cellgenic is building out commercial operations there too,” said David Christensen, Chief Executive Officer and President of Regenerative Medical Technology Group, Inc. “That kind of coordination is exactly the model we want to replicate.”
About Regenerative Medical Technology Group, Inc.
Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG) is an SEC-reporting regenerative medicine company operating through its wholly owned subsidiary Global Stem Cells Group and Global Stem Cells Group’s operating divisions — Cellgenic, the International Society for Stem Cell Application (ISSCA), and Cellular Hope Institute. The Company’s network reaches physicians and patients across more than 30 countries, combining biologics and regenerative-medicine product commercialization, physician education and certification, and physician-directed clinical services. RMTG’s stated mission is to help physicians make the benefits of regenerative medicine available to patients worldwide.
About ISSCA
The International Society for Stem Cell Application (ISSCA), the physician-education division of Global Stem Cells Group and Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG), was founded in 2009 and has trained more than 12,000 physicians across more than 45 countries in regenerative medicine, longevity medicine, and related disciplines through certifications, fellowships, conferences, and online education.
Forward-Looking Statements
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, and other factors — including regulatory developments, market acceptance, operational execution, competitive conditions, currency and economic factors, and the Company’s ability to maintain compliance with applicable laws — that could cause actual results to differ materially from those expressed or implied. Words such as “plan,” “forecast,” “anticipate,” “estimate,” “project,” “intend,” “expect,” “should,” “believe,” and similar expressions are intended to identify forward-looking statements. These statements are based on management’s current expectations and are qualified in their entirety by the risks described more fully in the Company’s filings with the U.S. Securities and Exchange Commission. Any forward-looking statement regarding future revenues, market penetration, or operational expansion reflects management’s current belief only and should not be read as a guarantee of any outcome. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.
Contact
- Published in Press Releases
ISSCA Announces Santa Cruz, Bolivia Conference, October 23–24
FOR IMMEDIATE RELEASE
- New regenerative medicine conference set for Hotel Los Tajibos, Santa Cruz de la Sierra, October 23–24
- Event extends ISSCA’s physician education strategy further into Latin America
- Conference reflects continued regional demand for regenerative medicine training
MIAMI, FL — The International Society for Stem Cell Application (ISSCA), the physician-education division of Global Stem Cells Group and Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG), today announced ISSCA 126, its regenerative medicine conference in Santa Cruz de la Sierra, Bolivia, taking place October 23–24 at Hotel Los Tajibos.
The Santa Cruz conference extends ISSCA’s Latin American physician education strategy into a market the organization has not previously featured prominently in its conference calendar, complementing its established programming in Argentina, Brazil, and Colombia. The program includes ISSCA’s flagship and peptide-medicine certification tracks.
ISSCA said Bolivia represents continued regional demand for structured regenerative medicine training and reflects the organization’s strategy of expanding physician access market-by-market across Latin America.
“Every new country on ISSCA’s calendar represents physicians who didn’t have easy access to this kind of training before,” said David Christensen, Chief Executive Officer and President of Regenerative Medical Technology Group, Inc. “Bolivia is the next step in that expansion.”
About Regenerative Medical Technology Group, Inc.
Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG) is an SEC-reporting regenerative medicine company operating through its wholly owned subsidiary Global Stem Cells Group and Global Stem Cells Group’s operating divisions — Cellgenic, the International Society for Stem Cell Application (ISSCA), and Cellular Hope Institute. The Company’s network reaches physicians and patients across more than 30 countries, combining biologics and regenerative-medicine product commercialization, physician education and certification, and physician-directed clinical services. RMTG’s stated mission is to help physicians make the benefits of regenerative medicine available to patients worldwide.
About ISSCA
The International Society for Stem Cell Application (ISSCA), the physician-education division of Global Stem Cells Group and Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG), was founded in 2009 and has trained more than 12,000 physicians across more than 45 countries in regenerative medicine, longevity medicine, and related disciplines through certifications, fellowships, conferences, and online education.
Forward-Looking Statements
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, and other factors — including regulatory developments, market acceptance, operational execution, competitive conditions, currency and economic factors, and the Company’s ability to maintain compliance with applicable laws — that could cause actual results to differ materially from those expressed or implied. Words such as “plan,” “forecast,” “anticipate,” “estimate,” “project,” “intend,” “expect,” “should,” “believe,” and similar expressions are intended to identify forward-looking statements. These statements are based on management’s current expectations and are qualified in their entirety by the risks described more fully in the Company’s filings with the U.S. Securities and Exchange Commission. Any forward-looking statement regarding future revenues, market penetration, or operational expansion reflects management’s current belief only and should not be read as a guarantee of any outcome. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.
Contact
- Published in Press Releases
ISSCA Introduces New Longevity and Adjunctive Therapies Certification
FOR IMMEDIATE RELEASE
- New program addresses complementary and adjunctive technologies increasingly used in longevity and regenerative medicine practices
- Curriculum spans therapeutic plasma exchange, peptide medicine, IV therapy, and additional physician-directed technologies
- Certification helps physicians understand how multiple technologies fit within a comprehensive medical practice
MIAMI, FL — The International Society for Stem Cell Application (ISSCA), the physician-education division of Global Stem Cells Group and Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG), today announced a new educational program focused on complementary and adjunctive technologies increasingly incorporated into longevity and regenerative medicine practices.
Curriculum areas include therapeutic plasma exchange (TPE), EBOO/EVO, peptide medicine, IV therapy, longevity medicine, artificial intelligence, PEMF, photobiomodulation/red-light technologies, hyperbaric medicine, and other physician-directed complementary technologies.
ISSCA said the program is designed to help physicians understand how multiple adjunctive technologies may fit within a comprehensive medical practice, rather than certifying any single modality in isolation.
“Physicians aren’t choosing between one technology and another anymore — they’re building comprehensive practices,” said David Christensen, Chief Executive Officer and President of Regenerative Medical Technology Group, Inc. “This certification is designed around that reality.”
About Regenerative Medical Technology Group, Inc.
Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG) is an SEC-reporting regenerative medicine company operating through its wholly owned subsidiary Global Stem Cells Group and Global Stem Cells Group’s operating divisions — Cellgenic, the International Society for Stem Cell Application (ISSCA), and Cellular Hope Institute. The Company’s network reaches physicians and patients across more than 30 countries, combining biologics and regenerative-medicine product commercialization, physician education and certification, and physician-directed clinical services. RMTG’s stated mission is to help physicians make the benefits of regenerative medicine available to patients worldwide.
About ISSCA
The International Society for Stem Cell Application (ISSCA), the physician-education division of Global Stem Cells Group and Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG), was founded in 2009 and has trained more than 12,000 physicians across more than 45 countries in regenerative medicine, longevity medicine, and related disciplines through certifications, fellowships, conferences, and online education.
Forward-Looking Statements
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, and other factors — including regulatory developments, market acceptance, operational execution, competitive conditions, currency and economic factors, and the Company’s ability to maintain compliance with applicable laws — that could cause actual results to differ materially from those expressed or implied. Words such as “plan,” “forecast,” “anticipate,” “estimate,” “project,” “intend,” “expect,” “should,” “believe,” and similar expressions are intended to identify forward-looking statements. These statements are based on management’s current expectations and are qualified in their entirety by the risks described more fully in the Company’s filings with the U.S. Securities and Exchange Commission. Any forward-looking statement regarding future revenues, market penetration, or operational expansion reflects management’s current belief only and should not be read as a guarantee of any outcome. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.
Contact
- Published in Press Releases
ISSCA Announces Global Summit in Cancun, Mexico, September 25–27
FOR IMMEDIATE RELEASE
- Summit features specialized workshops and certification tracks alongside international faculty at the JW Marriott Cancun Resort & Spa
- Event is expected to draw more than 500 physicians, researchers, and regenerative medicine leaders to ISSCA’s flagship Cancun venue
- Global Summit contributes to ISSCA’s international education ecosystem and Global Stem Cells Group’s worldwide presence
MIAMI, FL — The International Society for Stem Cell Application (ISSCA), the physician-education division of Global Stem Cells Group and Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG), today announced its 2026 Global Summit — ISSCA 125 — taking place September 25–27 at the JW Marriott Cancun Resort & Spa.
The Summit is expected to draw more than 500 physicians and professionals, with hundreds already registered, across specialized workshops and certification tracks including the organization’s flagship and peptide-medicine certifications, alongside international faculty, published authors, researchers, and physicians and leaders across regenerative medicine, longevity, and biotechnology.
ISSCA, founded in 2009, has trained more than 12,000 physicians across more than 45 countries to date. The Global Summit is positioned as a flagship contribution to ISSCA’s international education ecosystem and Global Stem Cells Group’s broader global footprint.
“Cancun has become something of a home base for ISSCA’s most ambitious programming,” said David Christensen, Chief Executive Officer and President of Regenerative Medical Technology Group, Inc. “The Global Summit is where physicians from the widest range of countries come together in one place, and that’s exactly the kind of international network effect we’re trying to build.”
About Regenerative Medical Technology Group, Inc.
Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG) is an SEC-reporting regenerative medicine company operating through its wholly owned subsidiary Global Stem Cells Group and Global Stem Cells Group’s operating divisions — Cellgenic, the International Society for Stem Cell Application (ISSCA), and Cellular Hope Institute. The Company’s network reaches physicians and patients across more than 30 countries, combining biologics and regenerative-medicine product commercialization, physician education and certification, and physician-directed clinical services. RMTG’s stated mission is to help physicians make the benefits of regenerative medicine available to patients worldwide.
About ISSCA
The International Society for Stem Cell Application (ISSCA), the physician-education division of Global Stem Cells Group and Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG), was founded in 2009 and has trained more than 12,000 physicians across more than 45 countries in regenerative medicine, longevity medicine, and related disciplines through certifications, fellowships, conferences, and online education.
Forward-Looking Statements
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, and other factors — including regulatory developments, market acceptance, operational execution, competitive conditions, currency and economic factors, and the Company’s ability to maintain compliance with applicable laws — that could cause actual results to differ materially from those expressed or implied. Words such as “plan,” “forecast,” “anticipate,” “estimate,” “project,” “intend,” “expect,” “should,” “believe,” and similar expressions are intended to identify forward-looking statements. These statements are based on management’s current expectations and are qualified in their entirety by the risks described more fully in the Company’s filings with the U.S. Securities and Exchange Commission. Any forward-looking statement regarding future revenues, market penetration, or operational expansion reflects management’s current belief only and should not be read as a guarantee of any outcome. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.
Contact
- Published in Press Releases
ISSCA Launches Peptide Certification 2.0 With Expanded Curriculum and Two New Reference Books
FOR IMMEDIATE RELEASE
- Major expansion of ISSCA’s peptide education program includes updated modules, practical resources, and two new physician reference books
- Program addresses dosing frameworks, combination strategies, preparation, and protocol development within applicable medical and regulatory frameworks
- Peptide Certification 2.0 builds on ISSCA’s existing physician education infrastructure
MIAMI, FL — The International Society for Stem Cell Application (ISSCA), the physician-education division of Global Stem Cells Group and Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG), today announced Peptide Certification 2.0, a major expansion of its peptide medicine education and certification program.
The updated program includes expanded curriculum modules, updated educational materials, practical physician resources, and two new specialized peptide reference guides addressing dosing frameworks, combination strategies, preparation, and protocol development within applicable medical and regulatory frameworks.
ISSCA positioned Peptide Certification 2.0 as a comprehensive physician-focused educational resource, building on the organization’s existing peptide certification track offered at its conference programming across Latin America, the Middle East, and other regions.
“Peptide medicine has moved fast, and the education has to keep pace with it,” said David Christensen, Chief Executive Officer and President of Regenerative Medical Technology Group, Inc. “Version 2.0 gives physicians a genuinely updated curriculum and two reference resources they can use in daily practice.”
About Regenerative Medical Technology Group, Inc.
Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG) is an SEC-reporting regenerative medicine company operating through its wholly owned subsidiary Global Stem Cells Group and Global Stem Cells Group’s operating divisions — Cellgenic, the International Society for Stem Cell Application (ISSCA), and Cellular Hope Institute. The Company’s network reaches physicians and patients across more than 30 countries, combining biologics and regenerative-medicine product commercialization, physician education and certification, and physician-directed clinical services. RMTG’s stated mission is to help physicians make the benefits of regenerative medicine available to patients worldwide.
About ISSCA
The International Society for Stem Cell Application (ISSCA), the physician-education division of Global Stem Cells Group and Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG), was founded in 2009 and has trained more than 12,000 physicians across more than 45 countries in regenerative medicine, longevity medicine, and related disciplines through certifications, fellowships, conferences, and online education.
Forward-Looking Statements
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, and other factors — including regulatory developments, market acceptance, operational execution, competitive conditions, currency and economic factors, and the Company’s ability to maintain compliance with applicable laws — that could cause actual results to differ materially from those expressed or implied. Words such as “plan,” “forecast,” “anticipate,” “estimate,” “project,” “intend,” “expect,” “should,” “believe,” and similar expressions are intended to identify forward-looking statements. These statements are based on management’s current expectations and are qualified in their entirety by the risks described more fully in the Company’s filings with the U.S. Securities and Exchange Commission. Any forward-looking statement regarding future revenues, market penetration, or operational expansion reflects management’s current belief only and should not be read as a guarantee of any outcome. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.
Contact
- Published in Press Releases
ISSCA Expands Global Online Academy With New Curriculum Modules
FOR IMMEDIATE RELEASE
- Expansion adds modules covering biologics, exosomes, MSCs, NK cells, dendritic cells, immunotherapy, CAR-T science, peptide medicine, and longevity medicine
- Next generation of ISSCA’s Online Academy broadens physician access to regenerative medicine education
- Curriculum growth complements ISSCA’s in-person conference and certification programs
MIAMI, FL — The International Society for Stem Cell Application (ISSCA), the physician-education division of Global Stem Cells Group and Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG), today announced the next generation of its Online Academy, adding curriculum modules covering biologics, exosomes, mesenchymal stromal/stem cells (MSCs), Natural Killer cells, dendritic cells, immunotherapy, CAR-T cell science, peptide medicine, longevity medicine, and other emerging regenerative technologies.
The expanded Academy is designed to give physicians outside ISSCA’s in-person conference markets ongoing access to structured, updated regenerative-medicine education. ISSCA said the expansion reflects sustained physician demand for digital-first education formats alongside its conference and certification programming.
The organization was clear that Online Academy modules constitute physician education and do not themselves authorize any physician to administer a particular therapy — authorization remains governed by each physician’s own licensure and applicable local regulation.
“Not every physician can travel to a conference for every new modality,” said David Christensen, Chief Executive Officer and President of Regenerative Medical Technology Group, Inc. “Expanding the Online Academy is how ISSCA keeps a much larger physician population current, between the in-person events we run around the world.”
About Regenerative Medical Technology Group, Inc.
Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG) is an SEC-reporting regenerative medicine company operating through its wholly owned subsidiary Global Stem Cells Group and Global Stem Cells Group’s operating divisions — Cellgenic, the International Society for Stem Cell Application (ISSCA), and Cellular Hope Institute. The Company’s network reaches physicians and patients across more than 30 countries, combining biologics and regenerative-medicine product commercialization, physician education and certification, and physician-directed clinical services. RMTG’s stated mission is to help physicians make the benefits of regenerative medicine available to patients worldwide.
About ISSCA
The International Society for Stem Cell Application (ISSCA), the physician-education division of Global Stem Cells Group and Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG), was founded in 2009 and has trained more than 12,000 physicians across more than 45 countries in regenerative medicine, longevity medicine, and related disciplines through certifications, fellowships, conferences, and online education.
Forward-Looking Statements
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, and other factors — including regulatory developments, market acceptance, operational execution, competitive conditions, currency and economic factors, and the Company’s ability to maintain compliance with applicable laws — that could cause actual results to differ materially from those expressed or implied. Words such as “plan,” “forecast,” “anticipate,” “estimate,” “project,” “intend,” “expect,” “should,” “believe,” and similar expressions are intended to identify forward-looking statements. These statements are based on management’s current expectations and are qualified in their entirety by the risks described more fully in the Company’s filings with the U.S. Securities and Exchange Commission. Any forward-looking statement regarding future revenues, market penetration, or operational expansion reflects management’s current belief only and should not be read as a guarantee of any outcome. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.
Contact
- Published in Press Releases
